changes in protein profiles in bortezomib applied multiple myeloma ...
changes in protein profiles in bortezomib applied multiple myeloma ...
changes in protein profiles in bortezomib applied multiple myeloma ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
CHAPTER 4<br />
RESULTS AND DISCUSSION<br />
4.1. Cytotoxic Effects of Bortezomib on U-266 Cells<br />
MM U-266 cells were treated with <strong>in</strong>creas<strong>in</strong>g concentrations of Bortezomib for<br />
72 hours and XTT cell proliferation assay was carried out <strong>in</strong> order to determ<strong>in</strong>e the anti-<br />
proliferative effects of agent on these cells. The cells were exposed to Bortezomib from<br />
0.1 to 70 nM and the results showed that there was a dose-dependent decrease <strong>in</strong> cell<br />
proliferation as compared to untreated controls. There were 3, 4, 15, 32, 57, 73 and 79%<br />
decrease of cell proliferation when the cells were exposed to 0.1, 1, 5, 10, 20, 50 and 70<br />
nM Bortezomib, respectively (Figure 4.1). As a result, the <strong>in</strong>hibitory concentration<br />
(IC50) value of Bortezomib on MM U-266 cells was calculated from cell proliferation<br />
plots and found to be 17 nM. (Figure 4.1).<br />
% Cell Proliferation <strong>in</strong> XTT<br />
120<br />
100<br />
80<br />
60<br />
40<br />
20<br />
0<br />
XTT Cell Proliferation Test<br />
C 0,1 1 5 10 20 50 70<br />
Bortezomib (nM, 72h)<br />
Figure 4.1. XTT Cell Proliferation Result<br />
U-266<br />
68